MCID: HPT073
MIFTS: 72

Hepatitis C Virus

Categories: Genetic diseases, Rare diseases, Gastrointestinal diseases, Liver diseases, Immune diseases, Endocrine diseases, Infectious diseases

Aliases & Classifications for Hepatitis C Virus

MalaCards integrated aliases for Hepatitis C Virus:

Name: Hepatitis C Virus 57
Hepatitis C Virus, Susceptibility to 57 29 6 40
Hepatitis C Virus Infection, Response to Therapy of 57 29 6
Response to Antiviral Treatment in Hepatitis C 59
Hepatitis C Virus, Response to Therapy of 57
Response to Peg/ifn-Ribavirin in Hcv 59
Hepatitis C Virus, Resistance to 57
Resistance to Hepatitis C Virus 6
Hcv, Susceptibility to 57
Hcv 57

Classifications:



External Ids:

OMIM 57 609532
Orphanet 59 ORPHA284102

Summaries for Hepatitis C Virus

OMIM : 57 HCV, which is principally transmitted by blood, infects about 3% of the world's population. HCV infection causes acute hepatitis, which is self-resolving in 20 to 50% of cases but does not confer permanent immunity. In 50 to 80% of cases, HCV infection becomes chronic and results in chronic hepatitis, cirrhosis, and hepatocellular carcinoma. As a result, HCV infection is a leading killer worldwide and the most common cause of liver failure in the U.S. HCV is opportunistic in individuals infected with human immunodeficiency virus (HIV; see 609423), approximately 25% of whom are coinfected with HCV. HCV infection is also associated with cryoglobulinemia (see 123550), a B-lymphocyte proliferative disorder (Pawlotsky, 2004; Chisari (2005); Pileri et al., 1998). (609532)

MalaCards based summary : Hepatitis C Virus, also known as hepatitis c virus, susceptibility to, is related to hepatitis c and hepatitis. An important gene associated with Hepatitis C Virus is IFNG (Interferon Gamma), and among its related pathways/superpathways are Cell adhesion molecules (CAMs) and IL12-mediated signaling events. The drugs Miconazole and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection and homeostasis/metabolism

Wikipedia : 76 Hepatitis C virus (HCV) is a small (55–65 nm in size), enveloped, positive-sense single-stranded RNA... more...

Related Diseases for Hepatitis C Virus

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis C Virus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 348)
# Related Disease Score Top Affiliating Genes
1 hepatitis c 34.0 CD81 CLDN1 CLDN6 CLDN9 CLEC4M GPT
2 hepatitis 33.3 CD81 CLDN1 CLDN6 CLDN9 GPT IFNL4
3 hepatitis b 32.2 DDX3X GPT IFNG PSMA7
4 autoimmune hepatitis 31.4 GPT HLA-DRB1 KRT8
5 multiple sclerosis 27.9 CCR5 HLA-DRB1 IFNG PTPRC
6 recurrent hepatitis c virus induced liver disease in liver transplant recipients 12.2
7 hepatocellular carcinoma 11.6
8 fibrillary glomerulonephritis 11.0
9 gianotti crosti syndrome 11.0
10 immunotactoid glomerulopathy 11.0
11 immunotactoid or fibrillary glomerulopathy 11.0
12 hemorrhagic fever 11.0 GPT HLA-DRB1 IFNG
13 cholangitis 11.0 CLDN1 GPT HLA-DRB1
14 berylliosis 10.9 HLA-DRB1 IFNG
15 chronic beryllium disease 10.8 HLA-DRB1 IFNG
16 cryoglobulinemia 10.8
17 eosinophilia-myalgia syndrome 10.7 HLA-DRB1 IFNG
18 cryoglobulinemia, familial mixed 10.7
19 liver disease 10.6
20 glomerulonephritis 10.5
21 lymphoma 10.5
22 membranoproliferative glomerulonephritis 10.4
23 porphyria cutanea tarda 10.4
24 porphyria 10.4
25 vasculitis 10.4
26 liver cirrhosis 10.4
27 diabetes mellitus, noninsulin-dependent 10.3
28 lichen planus 10.3
29 type i 10.3
30 oral lichen planus 10.3
31 b-cell lymphomas 10.2
32 arthritis 10.2
33 type ii mixed cryoglobulinemia 10.2
34 cholangiocarcinoma 10.1
35 thalassemia 10.1
36 thyroiditis 10.1
37 membranous nephropathy 10.1
38 leukemia 10.1
39 kidney disease 10.1
40 chronic kidney failure 10.1
41 thrombocytopenia 10.1
42 viral hepatitis 10.1
43 hepatitis d 10.1
44 hemophilia 10.1
45 alcoholic hepatitis 10.0
46 diffuse large b-cell lymphoma 10.0
47 hepatitis a 10.0
48 aging 10.0
49 fatty liver disease, nonalcoholic 1 10.0
50 diarrhea 10.0

Graphical network of the top 20 diseases related to Hepatitis C Virus:



Diseases related to Hepatitis C Virus

Symptoms & Phenotypes for Hepatitis C Virus

Clinical features from OMIM:

609532

GenomeRNAi Phenotypes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection GR00233-A-1 9.1 CD81 CLDN1 DDX3X GPT HM13 PNKD

MGI Mouse Phenotypes related to Hepatitis C Virus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.03 ATG5 CCR5 CD81 CLDN1 CLEC4M DDX3X
2 hematopoietic system MP:0005397 10.02 ATG5 CCR5 CD81 CLEC4M HM13 IFNG
3 immune system MP:0005387 9.85 HM13 IFNG IFNL3 KRT8 PTPRC SCARB1
4 liver/biliary system MP:0005370 9.5 PTPRC SCARB1 ATG5 CCR5 HM13 IFNG
5 nervous system MP:0003631 9.32 ATG5 CCR5 CD81 CLDN9 DDX3X HM13

Drugs & Therapeutics for Hepatitis C Virus

Drugs for Hepatitis C Virus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 580)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
2
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
3
Ezetimibe Approved Phase 4,Phase 2,Phase 1 163222-33-1 150311
4
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 36791-04-5 37542
5
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
6
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
7
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 198153-51-4 5360545
8
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
9
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
10
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99210-65-8, 215647-85-1
11
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
12
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
13
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
14
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 143491-57-0 60877
15
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
16
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76-99-3 4095
17
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 155213-67-5 392622
18
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
19
Ledipasvir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1256388-51-8 67505836
20
Sofosbuvir Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1190307-88-0 45375808
21
Insulin Glargine Approved Phase 4 160337-95-1
22
Insulin glulisine Approved Phase 4 207748-29-6
23
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6 23994
24
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3 142217-69-4 153941
25
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 1
26
Simeprevir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 923604-59-5 66576988
27
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128794-94-5 5281078
28
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 24280-93-1 446541
29
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
30
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
31
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 154598-52-4 64139
32
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 134678-17-4 60825
33
Zidovudine Approved Phase 4,Phase 1,Phase 2 30516-87-1 35370
34
Interferon alfacon-1 Approved, Investigational Phase 4,Phase 3,Phase 2 118390-30-0 9554198
35
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 192725-17-0 92727
36
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 152923-56-3, 179045-86-4
37
Heroin Approved, Illicit, Investigational Phase 4,Phase 3,Not Applicable 561-27-3 5462328
38
Nevirapine Approved Phase 4 129618-40-2 4463
39
Rifaximin Approved, Investigational Phase 4,Phase 2,Not Applicable 80621-81-4 6436173
40
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
41
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 5284616 6436030 46835353
42
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
43
Cobicistat Approved Phase 4,Phase 3,Phase 1 1004316-88-4
44
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
45
Losartan Approved Phase 4 114798-26-4 3961
46
Iron Approved Phase 4,Phase 2,Not Applicable 7439-89-6 23925
47
Nelfinavir Approved Phase 4 159989-64-7 64143
48
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1 59729-33-8 2771
49
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
50
Ethanol Approved Phase 4,Phase 2,Phase 1,Not Applicable 64-17-5 702

Interventional clinical trials:

(show top 50) (show all 2271)
# Name Status NCT ID Phase Drugs
1 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
2 Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
3 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4 Reiferon retard
4 Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
5 Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC) Unknown status NCT02745132 Phase 4
6 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
7 Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
8 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
9 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
10 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
11 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
12 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
13 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
14 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
15 Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
16 Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
17 PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR) Unknown status NCT01056172 Phase 4 Peginterferon alfa-2a and Ribavirin;Peginterferon alfa-2a and Ribavirin
18 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
19 Nutritional Support During Antiviral Therapy for Hepatitis C Unknown status NCT00841243 Phase 4
20 Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
21 Endothelial Dysfunction and Subclinical Atheromatosis in Chronic HCV Infection. Response to DAA Agents. Unknown status NCT02802280 Phase 4
22 Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
23 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
24 Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
25 36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8 Unknown status NCT01683786 Phase 4 Pegintron + Riba
26 Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients Unknown status NCT00526448 Phase 4 ribavirin;ribavirin;Peginterferon alfa-2a;epoetin beta
27 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
28 Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease Unknown status NCT02691728 Phase 4 LDV/SOF FDC
29 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
30 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
31 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
32 Hemostasis in Kocher-Langenbeck Approaches for Acetabular Surgery Using a Topical Surgical Hemostat (Vitagel) Unknown status NCT01230931 Phase 4
33 Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT) Completed NCT02624063 Phase 4 Daclatasvir + Sofosbuvir;Simeprevir + Sofosbuvir
34 Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients Completed NCT01469884 Phase 4 Everolimus;Cyclosporine;Tacrolimus
35 Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation Completed NCT00821587 Phase 4 Cyclosporine;Tacrolimus
36 Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C) Completed NCT02768961 Phase 4 sofosbuvir;ledipasvir
37 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease Completed NCT00028093 Phase 4 Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a
38 Treatment of Recently Acquired Hepatitis C Virus Infection Completed NCT01336010 Phase 4 Peginterferon alfa-2a;Ribavirin
39 Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV) Completed NCT01134952 Phase 4 Mycophenolate to sirolimus switch
40 Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3 Completed NCT00143000 Phase 4 Peginterferon alfa-2a 40KD and Ribavirin
41 The SIM-SOF Trial for Hepatitis C Completed NCT02168361 Phase 4 Pegylated Interferon alfa-2b;Simeprevir;Ribavirin;Sofosbuvir
42 Australian Trial in Acute Hepatitis C Completed NCT00192569 Phase 4 Pegylated Interferon alfa 2a;Ribavirin (HIV conifected patients only)
43 Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World Completed NCT02964091 Phase 4 sofosbuvir/ledipasvir
44 Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C Completed NCT00938860 Phase 4 cyclosporin (Neoral);tacrolimus (Prograf)
45 A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3 Completed NCT01258101 Phase 4 peginterferon alfa-2a [Pegasys];peginterferon alfa-2a [Pegasys];ribavirin;ribavirin
46 Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection Completed NCT01097395 Phase 4 ribavirin
47 Treatment of Acute Hepatitis C Virus in HIV Co-Infection Completed NCT00845676 Phase 4 Pegylated interferon alfa-2a + Ribavirin
48 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
49 Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C Completed NCT00917358 Phase 4 Pegylated interferon alfa-2a
50 Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin

Search NIH Clinical Center for Hepatitis C Virus

Genetic Tests for Hepatitis C Virus

Genetic tests related to Hepatitis C Virus:

# Genetic test Affiliating Genes
1 Hepatitis C Virus, Susceptibility to 29 CCR5 IFNG IFNL3 PTPRC
2 Hepatitis C Virus Infection, Response to Therapy of 29

Anatomical Context for Hepatitis C Virus

MalaCards organs/tissues related to Hepatitis C Virus:

41
Liver, Testes, Kidney, T Cells, B Cells, Heart, Bone

Publications for Hepatitis C Virus

Articles related to Hepatitis C Virus:

(show top 50) (show all 4178)
# Title Authors Year
1
Hepatitis C virus infection in children in the era of direct-acting antiviral. ( 29962813 )
2018
2
Epidemiology and risk factors for hepatitis C virus infection in a high-prevalence population. ( 29429421 )
2018
3
Enhanced identification of maternal hepatitis C virus infection using existing public health surveillance systems. ( 29972246 )
2018
4
Contradictory intrahepatic immune responses activated in high-load hepatitis C virus livers compared with low-load livers. ( 29248968 )
2018
5
Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A. ( 29235977 )
2018
6
Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV. ( 29438195 )
2018
7
Hepatitis C virus infection and risk of osteoporotic fracture: A systematic review and meta-analysis. ( 29322660 )
2018
8
Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis. ( 29971486 )
2018
9
Safety and Efficacy of Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection in Patients with I^-Thalassemia Major. ( 29743790 )
2018
10
HIV and hepatitis C virus infections in Quebec's provincial detention centres: comparing prevalence and related risky behaviours between 2003 and 2014-2015. ( 29981093 )
2018
11
Direct-acting Antiviral Agents in Hepatitis C Virus-infected Renal Allograft Recipients: Treatment and Outcome Experience from Single Center. ( 29962673 )
2018
12
Hepatitis C virus E2 envelope glycoprotein induces an immunoregulatory phenotype in macrophages. ( 29443378 )
2018
13
Association of killer cell immunoglobulin-like receptors with spontaneous clearance of hepatitis C virus in the Chinese population. ( 29446443 )
2018
14
Sofosbuvir and Ledipasvir is Associated with High Sustained Virologic Response and Improvement of Health-Related Quality of Life in East Asian Patients with Hepatitis C Virus Infection. ( 29974665 )
2018
15
Future Considerations for the Evaluation of Hepatitis C Virus Treatments in Pan-Genotypic Therapy for Noncirrhotic Treatment-Naive Patients. ( 29290175 )
2018
16
Psychiatric and functional neuroimaging abnormalities in chronic hepatitis C virus patients: Is vasculitis a contributing factor? ( 29935864 )
2018
17
Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study. ( 29438397 )
2018
18
Role of Direct-Acting Antivirals in Hepatitis C Virus-Positive Castleman Disease. ( 29557805 )
2018
19
Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study. ( 29271782 )
2018
20
microRNA-122 amplifies hepatitis C virus translation by shaping the structure of the internal ribosomal entry site. ( 29973597 )
2018
21
Association of interferon lambda polymorphisms with elevated baseline viral loads in chronic hepatitis C virus genotype 6 infection. ( 29022122 )
2018
22
Hepatitis C virus incidence in HIV-infected and in preexposure prophylaxis (PrEP)-using men having sex with men. ( 29959866 )
2018
23
Mother-to-child transmission of hepatitis C virus. ( 29968442 )
2018
24
Hepatitis C virus infection in chronic kidney disease: paradigm shift in management. ( 29961309 )
2018
25
Induction of genotype-cross reactive, hepatitis C virus-specific cell mediated immunity in DNA-vaccinated mice. ( 29437963 )
2018
26
Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried-Blood Spot Samples. ( 29959023 )
2018
27
Long-term familial Mediterranean fever remission on successful hepatitis C virus treatment in a patient not responding to colchicine: a case report. ( 29773081 )
2018
28
The prevalence of hepatitis C virus infection in thalassemia patients in Iran from 2000 to 2017: a systematic review and meta-analysis. ( 29411135 )
2018
29
Atypical generalized morphea-like scleroderma occurring in a patient exposed to organic solvents and having chronic hepatitis C virus infection. ( 29451196 )
2018
30
Monoclonal antibodies against occludin completely prevented hepatitis C virus infection in a mouse model. ( 29437969 )
2018
31
The next wave of hepatitis C virus: The epidemic of intravenous drug use. ( 29427493 )
2018
32
Conformational Flexibility in the CD81-Binding Site of the Hepatitis C Virus Glycoprotein E2. ( 29967619 )
2018
33
Complete response of diffuse large B-cell lymphoma after direct-acting antiviral therapy for hepatitis C virus. ( 29432921 )
2018
34
Seroprevalence of hepatitis C virus among the newcomer students, Kafrelsheikh University, Egypt. ( 29981144 )
2018
35
A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan. ( 29429413 )
2018
36
Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV coinfected patients with mixed cryoglobulinemia. ( 29870852 )
2018
37
Anti-Hepatitis C Virus Activity of Uridine Derivatives of 2-Deoxy Sugars. ( 29954068 )
2018
38
Dual inhibitors of hepatitis C virus and hepatocellular carcinoma: design, synthesis and docking studies. ( 29255624 )
2018
39
Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3/NS4A protease inhibitors in SALo Paulo state. ( 29961118 )
2018
40
N-Myc Downstream-Regulated Gene 1 Restricts Hepatitis C Virus Propagation by Regulating Lipid Droplet Biogenesis and Viral Assembly. ( 29118118 )
2018
41
Liver stiffness reduction and serum fibrosis score improvement in HIV/hepatitis C virus-coinfected patients treated with direct-acting antivirals. ( 29953713 )
2018
42
Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus. ( 29439971 )
2018
43
Determinants in the Ig Variable Domain of Human HAVCR1 (TIM-1) Are Required To Enhance Hepatitis C Virus Entry. ( 29321304 )
2018
44
Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design. ( 29977246 )
2018
45
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens. ( 29318374 )
2018
46
Notes from the Field: Underreporting of Maternal Hepatitis C Virus Infection Status and the Need for Infant Testing - Oregon, 2015. ( 29447143 )
2018
47
Hepatitis C virus core+1/ARFP modulates Cyclin D1/pRb pathway and promotes carcinogenesis. ( 29444947 )
2018
48
Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis. ( 29857143 )
2018
49
Improvement of Proteinuria due to Combination Therapy with Daclatasvir and Asunaprevir in Hepatitis C Virus-associated Renal Disease without Cryoglobulinemia: A Case Report. ( 29526955 )
2018
50
The Complement System and C1q in Chronic Hepatitis C Virus Infection and Mixed Cryoglobulinemia. ( 29910796 )
2018

Variations for Hepatitis C Virus

ClinVar genetic disease variations for Hepatitis C Virus:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CCR5 NM_000579.3(CCR5): c.554_585del32 (p.Ser185Ilefs) deletion protective,risk factor rs333 GRCh37 Chromosome 3, 46414947: 46414978
2 CCR5 NM_000579.3(CCR5): c.554_585del32 (p.Ser185Ilefs) deletion protective,risk factor rs333 GRCh38 Chromosome 3, 46373456: 46373487
3 PTPRC PTPRC, 77C-G single nucleotide variant risk factor
4 IFNG NM_000619.2(IFNG): c.-893C> G single nucleotide variant drug response rs2069707 GRCh38 Chromosome 12, 68160508: 68160508
5 IFNG NM_000619.2(IFNG): c.-893C> G single nucleotide variant drug response rs2069707 GRCh37 Chromosome 12, 68554288: 68554288

Expression for Hepatitis C Virus

LifeMap Discovery
Genes differentially expressed in tissues of Hepatitis C Virus patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CXCL10 chemokine (C-X-C motif) ligand 10 Liver + 4.26 0.000
2 CXCL11 chemokine (C-X-C motif) ligand 11 Liver + 3.57 0.000
3 LOC553137 uncharacterized LOC553137 Liver - 3.21 0.000
4 CXCL9 chemokine (C-X-C motif) ligand 9 Liver + 3.07 0.000
Search GEO for disease gene expression data for Hepatitis C Virus.

Pathways for Hepatitis C Virus

Pathways related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.51 CLDN1 CLDN6 CLDN9 HLA-DRB1 PTPRC
2
Show member pathways
11.38 CCR5 HLA-DRB1 IFNG
3 11.14 CD81 CLDN1 CLDN6 CLDN9 SCARB1

GO Terms for Hepatitis C Virus

Cellular components related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 bicellular tight junction GO:0005923 9.33 CLDN1 CLDN6 CLDN9
2 cell surface GO:0009986 9.02 CCR5 HLA-DRB1 HM13 PTPRC SCARB1
3 apicolateral plasma membrane GO:0016327 8.96 CLDN6 KRT8

Biological processes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.73 CCR5 CD81 IFNG PTPRC
2 defense response to virus GO:0051607 9.62 IFNG IFNL3 IFNL4 PTPRC
3 viral entry into host cell GO:0046718 9.5 CD81 CLDN1 CLDN6 CLDN9 CLEC4M HLA-DRB1
4 cell-cell junction organization GO:0045216 9.43 CLDN1 CLDN6 CLDN9
5 regulation of T cell activation GO:0050863 9.4 IFNL3 IFNL4
6 viral process GO:0016032 9.4 CCR5 CD81 CLDN1 CLDN6 CLDN9 CLEC4M
7 positive regulation of immune response GO:0050778 9.37 IFNL3 IFNL4
8 calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules GO:0016338 9.33 CLDN1 CLDN6 CLDN9

Molecular functions related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II protein complex binding GO:0023026 9.26 CD81 HLA-DRB1
2 structural molecule activity GO:0005198 9.26 CLDN1 CLDN6 CLDN9 KRT8
3 virus receptor activity GO:0001618 9.23 CCR5 CD81 CLDN1 CLDN6 CLDN9 CLEC4M
4 protein binding GO:0005515 10.09 ATG5 CCR5 CD81 CLDN1 CLDN6 CLDN9

Sources for Hepatitis C Virus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....